NEW YORK, NY / ACCESSWIRE / March 31, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Class Period: February 14, 2020 to March 9, 2020
Lead Plaintiff Deadline: May 12, 2020

According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.

Learn about your recoverable losses in INO: http://www.kleinstocklaw.com/pslra-1/inovio-pharmaceuticals-inc-loss-submission-form?id=5864&from=1

AnaptysBio, Inc. (NASDAQ:ANAB)
Class Period: October 10, 2017 to November 7, 2019
Lead Plaintiff Deadline: May 26, 2020

During the class period, AnaptysBio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in ANAB: http://www.kleinstocklaw.com/pslra-1/anaptysbio-inc-loss-submission-form?id=5864&from=1

Hanmi Financial Corporation (NASDAQ:HAFC)
Class Period: August 12, 2019 to January 28, 2020
Lead Plaintiff Deadline: May 26, 2020

The complaint alleges that during the class period Hanmi Financial Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the $40.7 million troubled loan that the Company disclosed on conference calls would necessitate further and future specific provisions for the Company – in the millions; (2) the same $40.7 million troubled loan would necessitate the Company to appraise and take personal property securing a portion of the amount of the loan; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in HAFC: http://www.kleinstocklaw.com/pslra-1/hanmi-financial-corporation-loss-submission-form?id=5864&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 583330

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AG Mortgage Investment Trust, Inc. ("AG Mortgage" or "the Company") (NYSE:MITT). Investors who purchased AG Mortgage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mitt.

The investigation concerns whether AG Mortgage and certain of its officers and/or directors have violated federal securities laws.

On March 27, 2020, AG Mortgage issued a press release disclosing that "[s]ince March 23, 2020, the Company and several of its subsidiaries have received notifications from several financing counterparties of alleged events of default under their financing agreements, and of certain of those counterparties' intentions to accelerate the Company's and such subsidiaries' performance obligations under the relevant agreements." AG Mortgage advised investors that "in the event of a default under one or more of those agreements, financial and other obligations under such agreements, and in some cases the Company's obligations as a guarantor, may be accelerated and the counterparties may take ownership of the securities pledged to secure the financing obligations by the Company or its subsidiaries" and that "[t]he Company and its subsidiaries also may be subject to penalties under those agreements and may suffer cross-default claims from its other lenders." On this news, AG Mortgage's stock price fell $1.20 per share, or 30.38%, to close at $2.75 per share on March 30, 2020.

If you are aware of any facts relating to this investigation, or purchased AG Mortgage shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/mitt. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 583329

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TEGNA, Inc. ("Tegna" or "the Company") (NYSE:TGNA). Investors who purchased Tegna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:

www.bgandg.com/tgna.

The investigation concerns whether Tegna and certain of its officers and/or directors have violated federal securities laws.

On March 29, 2020, Tegna announced that it had ceased discussions with parties interested in acquiring the Company, citing the disruptions caused by the COVID-19 pandemic. Then, on March 30, 2020, Standard General LP ("Standard General"), owner of 9.7% of Tegna's outstanding shares, issued a statement criticizing Tegna's approach to the acquisition offers. Standard General's founding partner Soo Kim stated that Tegna's "approach would be off market in any deal environment, and particularly so under current market conditions. . . . [Tegna's] board's actions appear designed to end this process before it can even begin in earnest. This is just the latest in a troubling pattern of behavior. It should never have come to this, and shareholders need to hold this board accountable." On this news, Tegna's stock price fell $2.53 per share, or 19.15%, to close at $10.68 per share on March 30, 2020.

If you are aware of any facts relating to this investigation, or purchased Tegna shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/tgna. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 583328

AI-Assisted Exam Proctoring Allows Postsecondary Students to Complete School Year

TORONTO, ON / ACCESSWIRE / March 31, 2020 / eCampusOntario and the provincial government have announced a partnership to support the province's colleges and universities whose academic year has been disrupted by the COVID-19 health emergency. All publicly assisted institutions will be provided access to an automated Artificial Intelligence-assisted proctoring tool on an as-needed basis to enable the delivery of final exams.

As alternative assessment strategies are being considered by institutions, this technology will fill a gap for courses that have unique assessment needs, especially those that are high impact, with admissions prerequisites or specific program needs. "We commend postsecondary institutions for their leadership and innovation in using alternative assessment approaches that have allowed students to demonstrate their learning during this challenging time," said Ross Romano, Minister of Colleges and Universities. "Our government will continue working with our postsecondary and health partners to provide updates and to protect the health and well-being of students and faculty, while ensuring students can continue to access the world-class education our institutions provide."

Organizations and educational institutions around the world have been developing business and academic continuity strategies in light of COVID-19, and eCampusOntario and the provincial government's approach is unique in scope and capacity. "Ensuring that tens of thousands of college and university students are safe and healthy is everyone's top priority", said Dr. Steven Murphy, President & Vice-Chancellor of Ontario Tech University and Co-Chair of eCampusOntario's Board. "The solutions proposed by eCampusOntario, in partnership with the province of Ontario, and the cooperation of our faculty, position our students well, and we look forward to ending a modified school year on a positive note."

eCampusOntario will facilitate access to secure educational technology and is committed to preserving privacy and the integrity of academic assessment. "A global public health crisis has compounded the end of the school year stress for students, educators, and families who support them," said Judith Morris, President and CEO of Lambton College and Co-Chair of eCampusOntario's Board. "So, we truly appreciate our provincial government working with eCampusOntario staff to assist our students and faculty in the completion of the academic year."

eCampusOntario is a publicly funded organization that was established to drive success in online and technology-enabled teaching and learning in Ontario by building partnerships, advancing the use of educational technology, and creating digital learning environments that are open and collaborative. Facilitating the integration of this technology, eCampusOntario is committed to preserving student privacy as well as the integrity of academic assessment.

Contacts:

Questions related to the proctoring tool should be directed to proctorsupport@ecampusontario.ca
Media-related questions should be directed to Daniel Roukema, Director of Communications at mediarelations@ecampusontario.ca

SOURCE: eCampusOntario

ReleaseID: 583323

LOS ANGELES, CA / ACCESSWIRE / March 31, 2020 / Carinsuranceplan.org has released a new blog post that explains the role of safety devices in making car insurance cheaper.

For more info and free car insurance quotes online, visit https://carinsuranceplan.org/how-safety-devices-can-lower-car-insurance-rates/

Insurance companies encourage drivers to get safe cars. Or, at least, improve the safety rating of the chosen vehicle. An unsafe car presents numerous risks for both companies and drivers. Insurers are worried about the risk of making a claim, while drivers should be worried about their lives. This is the main reason why insurance companies grant discounts to drivers that install safety devices or choose cars that come equipped with multiple safety features. The blog post presents a list of devices for which drivers will receive discounts. Each device is analyzed.

Adaptive cruise control, forward collision warning, ABS and lane departure warning are some of the most important safety devices. These systems rely on radars, cameras, and sensors to warn the driver to potential hazards. Some systems can even engage in automated braking when the car gets too close to another vehicle or structure. Lane departure systems use cameras to monitor lane markings and warn the driver when he leaves the lane. Advanced systems may even automatically steer to bring the car on the correct lane.

For more examples, money-saving tips and free quotes, visit https://carinsuranceplan.org

Carinsuranceplan.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

"Installing safety devices will not only reduce the chances of being involved in an accident but will also help you get better rates", said Russell Rabichev, Marketing Director of Internet Marketing Company.

CONTACT:

Company Name: Internet Marketing Company
Person for contact: Gurgu C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://carinsuranceplan.org

SOURCE: Internet Marketing Company

ReleaseID: 583278

THN102 met the primary efficacy endpoint by significantly reducing excessive daytime sleepiness in Parkinson's patients
THN102 consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment
Excellent tolerability in these Parkinson's patients

LYON, FRANCE / ACCESSWIRE / March 31, 2020 / Theranexus, a biopharmaceutical company innovating the treatment of neurological diseases and pioneering the development of drug candidates modulating the interaction between neurons and glial cells, has announced the success of its Phase II trial for drug candidate THN102 for Parkinson's disease.

Seventy-five Parkinson's patients with debilitating, excessive daytime sleepiness (EDS) were recruited in Europe and the United States. The study was a double-blind, placebo-controlled, crossover trial with a one-week washout period between each successive two-week treatment period. The treatments were given in random order and consisted of: THN102 200mg modafinil/2mg flecainide, THN102 200mg modafinil/18mg flecainide, or a placebo.

THN102 met the primary efficacy endpoint and significantly increased the proportion of patients no longer suffering from daytime sleepiness for the duration of the treatment

The trial demonstrated the efficacy of THN102 in doses of THN102 200mg modafinil/2mg flecainide ("THN102-200/2"), with significant superiority over the placebo in reducing EDS measured using the Epworth Sleepiness Scale (ESS – the most widely used sleepiness scale, ranging from 0 to 24). The ESS score improved by 3.9 points in patients after treatment with THN102-200/2. This improvement is highly significant (p=0.01) compared with that achieved by the placebo (2.4 points).

The proportion of patients no longer presenting excessive daytime sleepiness for the duration of the treatment (commonly defined as ESS<11, Johns, 1997) was considerably higher with THN102-200/2 than in the placebo group (27.5% v. 16.2% – p=0.05).

The other exploratory efficacy parameters used in the trial did not show a difference between THN102 and the placebo.

An excellent tolerability profile

The trial demonstrated the excellent tolerability profile of THN102 for the two doses tested. The trial also provided assurance, via various sections of the Unified Parkinson's Disease Rating Scale (UPDRS – the most widely used scale for Parkinson's disease), that THN102 did not affect the motor disorders or other symptoms that occur in patients.

A more detailed presentation of the results of the trial is now available on the company website.

Professor Jean-Christophe Corvol at Pitié Salpêtrière Hospital and the Brain Institute, a Parkinson's disease specialist and principal investigator for the trial, noted: "With aging populations and increasing numbers of elderly people, the number of patients affected by Parkinson's disease will continue to rise. The symptom addressed by THN102 – excessive daytime sleepiness in Parkinson's disease – affects around 40% of patients. It is particularly debilitating[1] [2] and represents one of the primary risk factors[3] for accidents, with considerable medical and economic consequences.[4] There is currently no approved treatment to mitigate these major impacts. The positive results achieved with THN102 in this trial are a tremendous step forward in treating this debilitating symptom."

Franck Mouthon, CEO of Theranexus, added, "We have taken a crucial step forward in the development of our most advanced drug candidate, THN102. I would like to thank all the patients and practitioners who contributed to the success of this trial. To our knowledge, THN102 is the only pharmaceutical development with demonstrated efficacy for this indication, affecting about 2 million patients in the major markets. The aim for Theranexus is now to join forces with an industrial partner to continue developing THN102. Finally, in addition to the value of this Phase II success for THN102, this new step also represents a significant endorsement of the therapeutic approach pursued by Theranexus and its potential for efficacy in patients."

About excessive daytime sleepiness in Parkinson's disease[5]

Excessive daytime sleepiness is the inability to stay awake and alert during waking hours. It can also cause unpredictable and irresistible sudden sleep attacks.

Sleepiness generally manifests itself during periods of inactivity (or reduced activity), such as reading or watching television, but it can also occur when driving if the car is at a standstill, for example when stuck in a traffic jam.

The prevalence of excessive daytime sleepiness is higher in Parkinson's disease patients than in the general population. It is thought that around 40% of people with Parkinson's disease suffer from excessive daytime sleepiness. These sleepiness episodes may be aggravated by dopaminergic drugs, and their frequency increases as the disease progresses.

Treating excessive daytime sleepiness is complex. A first step may be to try to improve nighttime sleep, but often, in the absence of a suitable pharmacological treatment, the approach involves lessening the sedative effects of dopamine agonists during the day by reducing the dose or replacing them with L-Dopa. This requires a delicate balance in order to maintain control over motor symptoms in these patients. Unfortunately, excessive daytime sleepiness often fails to respond to these changes; in these cases it is thought to be linked to impairments to some arousal circuits in the brain. Modafinil is sometimes prescribed off-label to treat this symptom, but there is little evidence of the efficacy of this treatment in clinical trials.

More information is available on the France Parkinson association website https://www.franceparkinson.fr/somnolence-diurne-excessive/ (in French).

ABOUT THE THN102 TRIAL FOR PARKINSON'S DISEASE

The Phase II clinical trial examined the tolerability and efficacy of THN102 (modafinil/flecainide combination) in 75 Parkinson's disease patients with EDS characterized by a score of 14 or more (out of 24) on the Epworth Sleepiness Scale. The multicenter study was conducted in Europe and the United States.

The study was a double-blind, placebo-controlled, crossover trial with a one-week washout period between each successive two-week period of the following treatments in random order: THN102 200mg modafinil/2mg flecainide, THN102 200mg modafinil/18mg flecainide, or a placebo.

The primary endpoint of the trial was tolerability. The primary efficacy endpoint was excessive daytime sleepiness (EDS). Various exploratory parameters for efficacy and pharmacokinetics were also evaluated.

For further information about the Phase II multicenter trial: https://clinicaltrials.gov/ct2/show/NCT03624920

ABOUT THERANEXUS

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as "glial cells") in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.

The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

More information at: www.theranexus.com

[1] Knie B. Excessive daytime sleepiness in patients with Parkinson's Disease. CNS Drugs 2011; 25 (3): 203-212- https://www.ncbi.nlm.nih.gov/pubmed/21323392

[2] Salawu F and Olokoba A. Excessive daytime sleepiness and unintended sleep episodes associated with Parkinson's Disease – https://www.ncbi.nlm.nih.gov/pubmed/25829994

[3] Spindler M. Daytime sleepiness is associated with falls in Parkinson's disease. J. Parkinson's Dis. 2013; 3(3): 387-391. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772981

[4] Ondo W. Daytime sleepiness and other sleep disorders in Parkinson's Disease. Neurology 2001; 57: 1392-1396. https://www.ncbi.nlm.nih.gov/pubmed/11673578

[5] Adapted from the factsheet on excessive daytime sleepiness from French patient advocacy group France Parkinson

Contacts

THERANEXUS
Thierry Lambert
Chief Financial Officer
investisseurs@theranexus.fr

ACTUS finance & communication
Caroline Lesage
Investor Relations
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
theranexus@actus.fr

FP2COM
Florence Portejoie
Media Relations Europe
+ 33 (0)6 07 76 82 83
fportejoie@fp2com.fr

ROONEYPARTNERS LLC
Kate Barrette
Media Relations US
+ 1 917.414.6962
kbarrette@rooneyco.com

SOURCE: Theranexus

ReleaseID: 583324

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / ​Let's take it back to 1998 when Enas Barkho was a Junior in high school who at an early age knew that one day cannabis would become recreational and change the world. Enas knew he would be a part of this evolution and would be a key player in bridging cannabis and music together. Enas was a cannabis connoisseur and an entrepreneur by the age of 17 who in 10 years would be the founder of one of the greatest cannabis brands known as Jetfuel. Enas, not being a stranger to creativity, likes hitting multiple birds with one stone. His track record of talent management as well as keeping strong public relations in the community while running a cannabis brand have not gone unnoticed. Enas played a critical role in having joined the claim to fame of administering hip hop management with creating pot to order the social piece of Los Angeles.

Jetfuel, known as a luxury weed brand, has a reputation of being high quality with a strong high and is being sold in various dispensaries in all of California. It's marketed by many different social media influencers as well as customers that like to post pictures and caption "JetfuelOG" on their social media accounts such as Instagram and Snapchat.

Recreational marijuana sales are up substantially from approximately $2.5 billion in 2018, the first year of licensed cannabis sales in California, in keeping with the evaluation by using multiple sales-monitoring firms. After a rocky start in 2018, outlets which have survived California's tough licensing are trying out and packaging guidelines are "battle-hardened" and stronger because of an influx of investment that has allowed them to take benefit of the state's big populace and pent-up demand for legal products, said numerous analysts for income-tracking firms. California being a global hotspot for hip hop and marijuana, Enas is successfully gaining market capitalization in both industries which is a very tough feat.

Enas, the founder of talent management group Face Card, has been in the creative industry for over 15 years. Enas and his team have managed artists such as Cypress hill, Talib Kweli and Xzibit. These rappers have been growing their platforms and user base rapidly as they focus on West Coast Hip Hop which is a re-emerging genre in the Hip Hop and R&B scene.

After managing such big artists, Enas wanted to venture off and see where else he could take artists' careers. As the artists were all pioneers in the marijuana space Enas quickly pivoted and started to invest heavily in creating brands in the cannabis industry labeling the brand "Jet Fuel". They have been creating a unique brand that offers a different, more high-end cannabis, with extremely high THC percentage, giving customers a very high-end product.

"JetfuelOG" is the strain of marijuana. The brand has a reputation for being high quality and consistent. It's one of the traditional brands emerging in the compliant market.

Media:
​Shazir Mucklai
shazir@imperium-pr.com

SOURCE: Imperium Group

ReleaseID: 583320

Adherence to oxygen and solubility in water are the two major characteristics of ammonium phosphate accounting for its multiplicity in the application.

DUBAI, UAE / ACCESSWIRE / March 31, 2020 / The global ammonium phosphate market, surpassed US$ 40 Bn in the year 2018, will grow at a moderate pace through 2019-2029. According to the latest report of Future Market Insights (FMI), growth in fire control applications across different residential and commercial buildings is primarily boosting the growth of ammonium phosphate market.

"Manufacturers in the market are focused to provide to abide by government regulations and replace the inorganic ammonium phosphate fertilizers with their organic versions. Market players are collaborating to expand their operational capacity," reports FMI.

For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1469

Ammonium Phosphate Market: Key Research Findings

Fire retardant applications will account for the enhanced adoption rate of ammonium phosphate through 2019-2029.
Fertilizers' application will generate a plethora of opportunities for the manufacturers in the market.
Mono-ammonium phosphate will witness a rapid surge in demand for its use in granular fertilizers.
Asia Pacific will continue to lead the global market by the end of 2029; North America to exhibit fast-paced growth.

Ammonium Phosphate Market: Key Growth Drivers

Rise in the application of ammonium phosphate as an acidity regulator and firming agent is driving the growth in the market.
The high demand of monobasic ammonium phosphate in fire extinguishers has a positive influence on market growth.
Increasing preference for mono-ammonium phosphate for its excellent storage and handling properties is pushing the adoption rate of ammonium phosphate ahead.
Augmenting consumption in developing economies such as India and China will supplement the progress of the ammonium phosphate market.
Joint ventures are boosting the capacity of the ammonium phosphate market.

Ammonium Phosphate Market: Key Impediments

Stringent regulations regarding the use of inorganic fertilizers are inversely affecting the proliferation of ammonium phosphate in the market.
Growing awareness about the environmental impact of ammonium phosphate-containing fertilizers is hampering the smooth market growth.

Explore the complete Ammonium Phosphate Market report with 97 illustrative figures, 23 data tables, and the table of contents. Also find a detailed market segmentation on https://www.futuremarketinsights.com/request-special-price/rep-gb-1469

Ammonium Phosphate Market: Competition Landscape

Market players are expanding their revenues by spreading their presence across different applications of ammonium phosphate. Acknowledging the growing awareness regarding the environment, manufacturers have shifted their focus towards organic fertilizers. They are exploring revenue opportunities in growing markets of North America and Europe. A joint venture has turned out to be a major growth strategy of established players, expanding their global footprint.

Explore Future Market Insights' detailed coverage on,

Hexafluoride Market: This research report from FMI offers deep-dive into insights that inform about revenue strategies, key growth drivers, and viable profitable opportunities, associated with the sulfur hexafluoride market.

Sodium Silicate Market: This FMI report provides an in-depth analysis of competition intensity and essential data about major players in the sodium silicate market.

Refinery Catalyst Market: This research report offers detailed on different researches used to analyze major market players, the potential size of the refinery catalyst market, and major collaborations in the market.

Gain access to Market Ngage, an AI-powered, real-time business intelligence platform that goes beyond the conventional research solutions to solve the complex strategy challenges that organizations face today.

About the Report

This FMI report provides regional and segmental analysis on the evolving trends in the market which impact the ammonium phosphate market. The report further provides important insights on the ammonium phosphate market based on product type (mono-ammonium phosphate, ammonium polyphosphate, and di-ammonium phosphate), application (fertilizers, food & beverages, detergent & soaps, fire extinguisher, and water treatment chemicals) in five prominent geographic regions (North America, Latin America, Europe, Asia Pacific, and MEA).

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Mr. Abhishek Budholliya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Market Report: https://www.futuremarketinsights.com/reports/ammonium-phosphates-market
Press Release Source: https://www.futuremarketinsights.com/press-release/ammonium-phosphates-market

SOURCE: Future Market Insights

ReleaseID: 583296

FORT LAUDERDALE, FL / ACCESSWIRE / March 31, 2020 / In today's modern age, digital marketing agencies abound, but few are backed by the level of expertise and track record of results that Next Level Marketing brings to the table.

As a full-service digital marketing firm, Next Level Marketing offers a range of performance-minded digital marketing services aimed at ensuring their clients earn an impressive ROI on dollars invested.

As part of their continued dedication to service and support, Next Level Marketing has recently launched a new website uniquely designed and tailored to cater to the diverse and evolving needs of their clients.

The New Website

Just like their business, the new website expertly leverages technology to serve as a resource for current and prospective clients alike. The website's intuitive layout and functionality offers exceptional navigation and ease of finding the right information fast.

Powered by high-performance servers and industry-leading security, the website runs smooth and fast, while also being mobile responsive.

Communication is a big part of what Next Level Marketing is about. As such, a core focus of the site is making sure visitors can easily and readily access support or sales staff. The site features live chat with real humans, a responsive and simple "get a quote" request form, click to call functionality and more.

The Next Level Marketing Difference

Next Level Marketing is one of the nation's leading marketing firms, having a depth and breadth of experience backed by an impressive resume of results that speak for themselves. Having worked with businesses ranging from local mom and pop operations to multinational Fortune 500 companies, Next Level Marketing is agile, capable and ready to tackle any challenge.

The full-service digital marketing agency specializes in the following industries: legal, healthcare, franchises, home services, Small/Med businesses, e-commerce, and Fortune 500 companies.

Services Include:

Search Engine Optimization

Local Map SEO

Pay Per Click Advertising

Display Advertising

Mobile Advertising

Social Media Advertising

Web Design and Development

Reputation Management

And more…

The NLM Approach

Unlike traditional digital marketing agencies that offer "tiered" packages and services, NLM sought to disrupt the industry and put their money where their mouth was. NLM is one of the few agencies willing to "bet" on the quality and reliability of their firm's capability to deliver a strong ROI.

The agency is what is known as an "incentive-based" management company, providing holistic comprehensive and inclusive digital marketing campaigns that are custom-tailored to the needs and goals of each client.

A Better Process Means Better Results

Discovery

At NLM it all begins with a comprehensive free audit covering SEO, SEM, SMM, and other digital initiatives. In conjunction with a competitive analysis, these results are utilized to develop a customized proposal.

Creation

An all-inclusive strategy custom-tailored to further the client's short, mid and long-term goals, initiatives and key performance indicators. The strategy often includes an omnichannel approach, leveraging various digital mediums to maximize ROI.

Evolution

The team at NLM keeps their thumbs on the pulse of technology, industry, market trends, and more to ensure their client's strategy accurately reflects market conditions to deliver reliable and consistent growth.

Unheard of Guarantees

As a performance-driven agency with plans centered on incentives NLM provides clients with some of the industry's most generous guarantees. Pay Per Click clients are guaranteed at minimum 3:1 return on investment within 1-2 months or management fees are waived. SEO clients are guaranteed to rank for a minimum of 20+ search terms within 3-months or fees are waived until that milestone is reached.

Sample Results From the Previous Month:

227,394 leads generated

194,843 qualified calls generated

390,281 E-commerce transactions completed

Increased client revenue by $229,746,267

Those interested in achieving similar results or who are interested in learning more about how NLM can help their business or brand are encouraged to reach out via their official website.

Contact: Tomas Gallo, (954) 299 7152

SOURCE: Next Level Marketing

ReleaseID: 583305

Companies active in the frozen bakery industry are focusing on leveraging the catering and tourism industries, for higher profit margins, in addition to producing gluten-free options for a wider consumer demographic.

DUBAI, UAE / ACCESSWIRE / March 31, 2020 / The frozen bakery market is projected to grow at an very healthy CAGR of 7.4% during the forecast period (2019-2029). A significant increase in consumer demand for convenience foods, resulting from hectic lifestyles is a predominant factor driving the sales of frozen bakery products. Emerging players are targeting millennial consumers, who prefer the low-cost frozen bakery items to increase their market share. The rising demand from hotel and catering industries will continue to boost growth of frozen bakery market, reveals Future Market Insights (FMI).

"The recent surge in catering and tourism has been a key driver to growth across Europe, trends which are not likely to change in the coming years," says the FMI analyst.

Request report sample with 250+ pages to gain in-depth market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-11162

Frozen Bakery Market – Key Takeaways

Frozen bread will remain a leading product in the market, driven by the demand for convenience foods during the forecast period.
Online channels of sales will gain significant CAGR through the forecast period, owing to high penetration of smartphones and the internet.
Hypermarkets and supermarkets will account for majority market share, in terms of distribution channels.
Europe will hold a leading position in the global market share, while Asia Pacific will display high growth.

Frozen Bakery Market – Key Driving Factors

The prevalence of hectic lifestyles and the resultant consumer preference for convenience foods is a major growth driver.
Rising demand from small- and large-scale coffee shops and food chains remains a key influencer.
The expansion of the hotel and catering industries in recent years supports overall market growth.
Easy year-round availability of frozen bakery goods is also a driver for global market growth.

Frozen Bakery Market – Key Constraints

Volatility in the prices of raw materials will remain a challenge for market players.
Higher preference among consumers for freshly baked products will also remain a major restraint for market players.

Explore the global frozen bakery market report with 128 illustrative figures, 128 data tables and the table of contents. You can also find a comprehensive market segmentation on https://www.futuremarketinsights.com/askus/rep-gb-11162

Competition Landscape

Key players in the frozen bakery market are Arytza AG, Dawn Food Products Inc., Grupo Bimbo, General Mills, Cargill, Lantmannen, Conagra brands, Cole's Quality Food Inc., Bridgford Foods Corporation, and Europastry. Majority of these players are investing in expanding their product portfolios and optimizing their sourcing processes. Moreover, mergers, acquisitions, and collaborations with small-scale, local players is a major strategy being adopted by market leaders.

More About the Report

The FMI's market research report of 300 pages offers comprehensive insights on frozen bakery market. The market is analyzed on the basis of product type (frozen cake and muffins, frozen pastry, frozen bread and biscuits, and frozen pizza crust), distribution channels (hypermarkets and supermarkets, catering and industrial, and online retailing), end user (artisanal bakers, hotels and restaurants, bakery chains, and food processing industries) across seven key regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Explore Extensive Coverage of FMI's Food & Beverages Landscape

Coconut Milk Market: Find detailed insights on the global coconut milk market with exhaustive segment-wide analysis, market statistics, key influencing factors, prominent players and critical developmental strategies adopted by them for a 10-year forecast period.

Plant Based Ice Creams Market: FMI's report on the global plant-based ice creams market offers a in-depth commentary on the market poised for prolific growth during 2017-2027. The study covers comprehensive evaluation of key impacting forces, revenue sources, and market leaders in addition to with essential market strategies.

Cacao Beans Market: Get a deep-dive analysis on the cacao beans market with essential insights on growth levers, opportunities, restraints, regulatory policies, regional market forecast and key forte of market leaders.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Market Report: https://www.futuremarketinsights.com/reports/frozen-bakery-market
Press Release Source: https://www.futuremarketinsights.com/press-release/frozen-bakery-market

SOURCE: Future Market Insights

ReleaseID: 583294